Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics Inc. (DGX) has filed a Form 144 indicating an intended sale of 8,269 common shares through Fidelity Brokerage Services.
- Aggregate market value: $1,384,230.60 (based on the market price on the filing date).
- Percentage of shares outstanding: approx. 0.0074 % of the 111,823,441 shares outstanding — an immaterial level.
- Anticipated sale date: 07 / 30 / 2025 on the NYSE.
- Source of shares: options granted on 18 Feb 2019 (3,045 shares) and 18 Feb 2020 (5,224 shares); cash was paid upon exercise.
No shares were sold during the prior three months, and the signer represents no undisclosed adverse information. The filer’s name, relationship to the issuer, and 10b5-1 plan data were not disclosed in the excerpt.